Rakovina secures exclusivity on kt-5000 target profile
Preview text: Rakovina secures exclusivity on kt-5000 target profile Rakovina secures exclusivity on…
Use this example
- Subject
- Rakovina secures exclusivity on kt-5000 target profile
- Preview text
- Rakovina secures exclusivity on kt-5000 target profile Rakovina secures exclusivity on…
- From
- ir@
rakovinatherapeutics.com - ESP
- Mailchimp
- Sent
- Thu Oct 15, 2026, 10:30 AM ET
- Size
- 72 KB
- Images
- 7
- Links
- 12, 2 of them buttons
- Subject length
- 54 characters
Against Rakovina Therapeutics's usual
Sent in the 10 AM hour, which holds 13% of its emails; 31% arrive in the 4 PM hour. The subject is 54 characters; its average is 70.
Email headers
What the brand's servers put on this email. Our receiving servers, the address we subscribed with and unsubscribe links are left out.
- From
- Rakovina Therapeutics <[email protected]>
- Reply-To
- Rakovina Therapeutics <[email protected]>
- Subject
- Rakovina secures exclusivity on kt-5000 target profile
- Date
- Thu, 15 Oct 2026 14:30:58 +0000
- Message-ID domain
- mail93.atl301.rsgsv.net
- Return-Path domain
- mail93.atl301.rsgsv.net
- DKIM signature
- d=mailchimpapp.net s=k3
- List-Unsubscribe
- Present, one-click
- Mailer
- Mailchimp Mailer
- Feedback-ID sender
- mc
Servers it passed through, newest first
- from localhost [127.0.0.1] by mail93.atl301.rsgsv.net with ESMTP
Other sending headers (names only): X-Campaign, X-campaignid, X-Report-Abuse, X-MC-User, X-Accounttype
Sent just before and after
| Oct 30, 2026 11:32 AM | AI narrows the focus for our brain-targeted cancer drug | |
| Oct 22, 2026 4:17 PM | kt-5000AI update: what we’ve shown, and what’s next | |
| Oct 18, 2026 4:14 PM | Rakovina secures exclusivity on kt-5000 target profile · Resent | |
| Oct 15, 2026 10:30 AM | Rakovina secures exclusivity on kt-5000 target profile (this email) | |
| Oct 1, 2026 4:18 PM | Rakovina partners with Celvion: what it means for our ATR program | |
| Sep 17, 2026 4:45 AM | Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member | |
| Sep 10, 2026 4:30 AM | Rakovina Therapeutics Announces Appointment of Professor Petra Hamerlik to its Board of Directors |
More from Rakovina Therapeutics
All Rakovina Therapeutics emailsAnnouncing our partnership with Artemis AI
Nov 10, 2026 12:27 PM
Live tomorrow: the kt-5000AI story with Kim Oishi, Dr. Mads Daugaard and Handol Kim
Nov 4, 2026 10:45 AM
AI narrows the focus for our brain-targeted cancer drug
Oct 30, 2026 11:32 AM
kt-5000AI update: what we’ve shown, and what’s next
Oct 22, 2026 4:17 PM
Rakovina secures exclusivity on kt-5000 target profile
Oct 18, 2026 4:14 PM · Resent
Rakovina partners with Celvion: what it means for our ATR program
Oct 1, 2026 4:18 PM
Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member
Sep 17, 2026 4:45 AM
Rakovina Therapeutics Announces Appointment of Professor Petra Hamerlik to its Board of Directors
Sep 10, 2026 4:30 AM
